EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes

Andreia Bilé-Silva, Antonio Lopez-Beltran, Henrique Rasteiro, Nuno Vau, Ana Blanca, Enrique Gomez, Frederico Gaspar, Liang Cheng

Virchows Archiv · 2023-03 · 482 (3) · 493-505

DOI: 10.1007/s00428-022-03481-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virchows Archiv, online erschienen am 05.01.2023. Verfasst von Andreia Bilé-Silva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Egas Moniz Hospital, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. Hauptthemen laut MEDLINE: Carcinoma, Giant Cell, Prostatic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Salud y Protección Social, Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report on the clinicopathologic features of 27 pleomorphic giant cell carcinoma (PGCC) cases of the prostate identified in 20 patients with an age range of 51 to 84 years (68 ± 9; median 71 years). Charlson comorbidity index ranged from 3 to 12. Serum PSA ranged from 4.30 to 662 ng/mL (median 13 ng/mL). On histologic examination, bizarre giant cells with pleomorphic nuclei characterized pleomorphic giant cell carcinoma of the prostate. PGCC component was present in 5% to 100%, with half of the patients presenting with ≥ 20%. Half of the patients initially presented with T4 and 26% with T3 disease. All patients were considered Gleason scores of 9 to 10 (ISUP grade 5). A combination of hormone therapy with chemotherapy with or without radiation therapy was applied in 68% of patients. On follow-up, 14 patients (52%) were alive with disease (1–69 months) or dead of disease (1–38 months). Patients diagnosed earlier with lower TNM stage had longer survival than those diagnosed at a later T-stage or with metastatic disease ( p = 0.02). The percentage of PGCC was not related to survival in the current study. Molecular alterations in 3 samples showed a microsatellite-stable disease with low tumor mutation burden and variable PTEN, PTCH1, KDM6A, ARv7, and PIK3CA loss/alteration, TP53 mutation, TMPRSS2-ERG fusion, and MYC, PIK3CB, RICTOR, or IRS2 amplification. Our findings suggest that PGCC is a rare and aggressive subtype of prostate carcinoma whose recognition may steer clinicians to adopt more aggressive treatments and investigate new therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Giant CellProstatic NeoplasmsMaleHumansMiddle AgedAgedAged, 80 and overProstateGiant CellsTranscription FactorsProstate-Specific Antigen

Stichwörter der Autor:innen

Castration-resistantGrade group 5Hormone-resistanceISUP 5Pleomorphic giant cell carcinomaProstate cancer

Substanzen

Transcription FactorsProstate-Specific Antigen

Autor:innen und Institutionen

  • Urology Department, Egas Moniz Hospital, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal.
  • Pathology Department, Champalimaud Clinical Centre, Lisbon, Portugal. em1lobea@uco.es.
  • Department of Morphological Sciences, Cordoba University Medical School, Cordoba, Spain. em1lobea@uco.es.
  • Pathology Department, Champalimaud Clinical Centre, Lisbon, Portugal.
  • Medical Oncology, Champalimaud Clinical Centre, Lisbon, Portugal.
  • Department of Urology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital (HURS), Cordoba, 14004, Spain.

Förderung

  • Ministerio de Salud y Protección Social
  • Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud

Zitieren

APA

Bilé-Silva, A., Lopez-Beltran, A., Rasteiro, H., Vau, N., Blanca, A., Gomez, E., Gaspar, F., & Cheng, L. (2023). Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes. Virchows Archiv, 482(3), 493-505. https://doi.org/10.1007/s00428-022-03481-7

Vancouver

Bilé-Silva A, Lopez-Beltran A, Rasteiro H, Vau N, Blanca A, Gomez E, et al. Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes. Virchows Archiv. 2023;482(3):493-505. doi:10.1007/s00428-022-03481-7

BibTeX
@article{BilSilva2023,
  author = {Bilé-Silva, Andreia and Lopez-Beltran, Antonio and Rasteiro, Henrique and Vau, Nuno and Blanca, Ana and Gomez, Enrique and Gaspar, Frederico and Cheng, Liang},
  title = {Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes},
  journal = {Virchows Archiv},
  year = {2023},
  volume = {482},
  number = {3},
  pages = {493--505},
  doi = {10.1007/s00428-022-03481-7}
}
Kostenlos starten →